Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Vancomycin remains the mainstay treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) despite increased treatment failures. Daptomycin has been shown to improve clinical outcomes in patients with BSIs caused by MRSA isolates with vancomycin MICs of >1 mg/l...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Claeys, Kimberly C., Zasowski, Evan J., Casapao, Anthony M., Lagnf, Abdalhamid M., Nagel, Jerod L., Nguyen, Cynthia T., Hallesy, Jessica A., Compton, Mathew T., Kaye, Keith S., Levine, Donald P., Davis, Susan L., Rybak, Michael J.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2016
Teme:
Clinical Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038271/
https://ncbi.nlm.nih.gov/pubmed/27431221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00227-16
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items